China’s Healthcare Reform Needs Resource Allocation Shift – Healthcare Officials
This article was originally published in PharmAsia News
Executive Summary
Fundamental shift in resource allocation, physician incentive systems and reforms to public hospitals critical say key healthcare officials.
You may also be interested in...
Will China's Enlarged Medical Insurance System Cover More Oncology Treatments?
SHANGHAI - Although China's pharmaceutical market slowed down in the first quarter of 2011 due to price cuts and policy headwinds, it still grew at 14.5% compared to the same period last year, according to data from investment brokerage Citi. Growth largely was driven by increasing medical expenses in the world second largest economy, and in particular was fueled by China's second and third-tier cities, away from the coast, which saw first quarter prescription drug growth rates between 20-30% year over year
Riding High And Scaling Up, Chindex Readies Business Model Rollout In China
American hospital operator and medical device distributor Chindex is riding strong midterm growth momentum built on its strong branding in China and will likely benefit hugely from China's healthcare reforms and growing middle class.
China Biotech Podcast: BIOSECURE Updates, Genmab/ProfoundBio Deal
In this mixed Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Pashadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed BIOSECURE Act in the US Congress and US-China biotech movements. Also discussed is how Chinese biotechs are becoming acquisition targets for overseas biotech companies, including the recent purchases of Profound by Genmab and AnHeart Theraputics by Nuvantion.